IQVIA Holdings Inc. with ticker code (IQV) now have 18 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $281.00 and $205.00 suggesting an average Analsyt target price of $247.22. Now with the previous closing price of $177.16 this would imply there is now a potential upside of 39.5%. The 50 day moving average now sits at $203.92 while the 200 day moving average is $208.61. The company has a market cap of 33.14B. The stock price for the company is currently is currently $181.00 USD
The potential market cap would be $46,251,415,768 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 31.05, revenue per share of $79.12 and a 4.79% return on assets.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
